Compare Johnson Controls International PLC (JCI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Johnson & Johnson — how do they compare? Johnson Controls International PLC trades at $157.38 (market cap $93.28B), while Johnson & Johnson trades at $261.54 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 6.6× Johnson Controls International PLC's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 65 Days and Johnson & Johnson for 129 Days on average.
| JCI | JNJ | |
|---|---|---|
Market Cap | $93.28B | $618.09B |
Volume | 2,786,476 | 6,050,983 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $278.43 |
52-Week Low | $105.55 | $186.00 |
Typical Hold Time | 65 Days | 129 Days |
Enterprise Value | $102.12B | $646.37B |
Dividend Yield | 1.04% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $157.44, up 0.97% on the day, reflecting strong momentum after beating earnings estimates for three consecutive quarters. The stock exhibits a bullish technical outlook, trading above key support levels, while fundamentals are supported by a 13.94% net income margin and robust ROE of 24.42%. Recent news highlights inclusion in AI industrial stock recommendations and strong Q3 2026 results with raised full-year guidance.
The outlook for JCI remains positive, driven by earnings outperformance and strong demand in thermal management and building systems. Key opportunities include expanding margins and strategic positioning in energy efficiency markets. Risks involve elevated valuation multiples and increasing debt-to-asset ratios, which could pressure the stock if growth moderates.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
